NeuroSense Therapeutics has postponed its pre-New Drug Submission meeting with Health Canada to May 2026 to incorporate additional clinical and biomarker data for its lead drug candidate, PrimeC. This extended data package aims to strengthen the regulatory case for PrimeC, which targets ALS and Alzheimer's disease by addressing multiple disease mechanisms. The company expects to release Alzheimer's study results soon and is advancing a Phase 3 trial for ALS. These steps aim to accelerate regulatory approval and patient access to this potentially disease-modifying therapy.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Solana (SOL) has gained about 30% from its June low, trading around $78 and surpassing its 50-day EMA. The token's upward momentum is supported by increased speculative trading and a new SuperTrend buy signal, the first since October 2025. However, i...
Kenmare Resources reported weaker-than-expected production in the first half of 2026 due to commissioning delays at its Wet Concentrator Plant A, with ilmenite output down 40% year on year in Q2. Despite this, shipments increased by 53% as the compan...
Ramsdens Holdings PLC shares rose 13.6% to 670p following an improved takeover offer from US pawnbroking group FirstCash. FirstCash increased its cash bid to 675p per share from 600p, raising the total offer value to up to £232 million, including div...
Alphamin Resources delivers strong free cash flow from its high-grade Bisie tin mine, maintaining consistent output of 20,000 tonnes per annum. Despite operational risks in the Democratic Republic of Congo, the company trades at a significant valuati...
